{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:28:00Z","timestamp":1792024080664,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["24116006"],"award-info":[{"award-number":["24116006"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pbb.2013.11.033","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T06:16:44Z","timestamp":1386051404000},"page":"137-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":335,"special_numbering":"C","title":["R (\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine"],"prefix":"10.1016","volume":"116","author":[{"given":"Ji-chun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2013.11.033_bb0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2013.11.033_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044","article-title":"Signaling pathways underlying the rapid antidepressant actions of ketamine","volume":"62","author":"Duman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.11.033_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"Hashimoto","year":"2009","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pbb.2013.11.033_bb0025","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.pnpbp.2010.06.013","article-title":"The role of glutamate on the action of antidepressants","volume":"35","author":"Hashimoto","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/14737175.2013.811894","article-title":"Therapeutic implications for NMDA receptors in mood disorders","volume":"13","author":"Hashimoto","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pbb.2013.11.033_bb0040","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pbb.2013.11.033_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0924-977X(97)00050-3","article-title":"The role of N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes","volume":"8","author":"Heresco-Levy","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2013.11.033_bb0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial","volume":"16","author":"Irwin","year":"2013","journal-title":"J Palliat Med"},{"key":"10.1016\/j.pbb.2013.11.033_bb0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.mp.4001551","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0060","first-page":"1186","article-title":"Ketamine: teaching an old drug new tricks","volume":"87","author":"Kohrs","year":"1998","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pbb.2013.11.033_bb0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0070","first-page":"1101","article-title":"Novel glutamatergic drugs for the treatment of mood disorders","volume":"9","author":"Lapidus","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pbb.2013.11.033_bb0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pbb.2013.11.033_bb0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.nbd.2013.09.004","article-title":"Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure","volume":"62","author":"Li","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pbb.2013.11.033_bb0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pbb.2013.11.033_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11920-007-0063-1","article-title":"The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects","volume":"9","author":"Maeng","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.pbb.2013.11.033_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","article-title":"Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors","volume":"698","author":"Moaddel","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.11.033_bb0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2011.244","article-title":"Ketamine as a novel antidepressant: from synapse to behavior","volume":"91","author":"Murrough","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pbb.2013.11.033_bb0105","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-0029-1237375","article-title":"Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series","volume":"43","author":"Paslakis","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15622970701714370","article-title":"Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report from two cases","volume":"10","author":"Paul","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187152707780363267","article-title":"The NMDA receptor as a therapeutic target in major depressive disorder","volume":"6","author":"Pittenger","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.pbb.2013.11.033_bb0125","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","article-title":"Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo","volume":"22","author":"Robson","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2013.11.033_bb0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1176\/appi.ajp.2013.13081034","article-title":"Ketamine for treatment-resistant depression: ready or not for clinical use","volume":"170","author":"Rush","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0135","unstructured":"Steiner K, Gangkofner S, Grunenwald JM. Racemic separation of ketamine. 1997. Patent number: 6,040,479. (March 21, 2000)."},{"key":"10.1016\/j.pbb.2013.11.033_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2013.11.033_bb0140","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00000542-200004000-00033","article-title":"Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine","volume":"92","author":"Yamakura","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2013.11.033_bb0160","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229.2010.511059","article-title":"Glutamatergic modulators: the future of treating mood disorders?","volume":"18","author":"Zarate","year":"2010","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.pbb.2013.11.033_bb0155","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.biopsych.2012.11.031","article-title":"Human biomarkers of rapid antidepressant effects","volume":"73","author":"Zarate","year":"2013","journal-title":"Biol Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713003328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713003328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:33:06Z","timestamp":1758774786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305713003328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":32,"alternative-id":["S0091305713003328"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2013.11.033","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R (\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2013.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}